X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14715) 14715
Magazine Article (432) 432
Newsletter (389) 389
Newspaper Article (222) 222
Book / eBook (88) 88
Book Chapter (41) 41
Web Resource (31) 31
Transcript (7) 7
Conference Proceeding (4) 4
Publication (4) 4
Book Review (3) 3
Dissertation (3) 3
Government Document (2) 2
Journal / eJournal (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12318) 12318
dermatology (8287) 8287
dermatologic agents - therapeutic use (7169) 7169
dermatologic agents (6990) 6990
female (5409) 5409
male (4972) 4972
adult (3800) 3800
formulae, receipts, prescriptions (3716) 3716
middle aged (3279) 3279
anti-bacterial agents - therapeutic use (3094) 3094
treatment outcome (2972) 2972
psoriasis (2619) 2619
psoriasis - drug therapy (2606) 2606
skin (2471) 2471
antibiotics, antitubercular (2414) 2414
dermatologic agents - administration & dosage (2367) 2367
aged (1914) 1914
dermatologic agents - adverse effects (1781) 1781
care and treatment (1682) 1682
adolescent (1618) 1618
drug therapy (1403) 1403
severity of illness index (1298) 1298
animals (1254) 1254
administration, topical (1231) 1231
child (1227) 1227
administration, cutaneous (1222) 1222
young adult (1097) 1097
double-blind (1088) 1088
analysis (1084) 1084
therapy (1073) 1073
skin diseases (953) 953
acne vulgaris - drug therapy (935) 935
efficacy (934) 934
health aspects (895) 895
pharmacology & pharmacy (884) 884
acne (804) 804
antibodies, monoclonal - therapeutic use (775) 775
skin diseases - drug therapy (755) 755
drug therapy, combination (734) 734
surgery (690) 690
skin - pathology (678) 678
research (662) 662
safety (653) 653
double-blind method (650) 650
infliximab (632) 632
anti-inflammatory agents - therapeutic use (627) 627
immunosuppressive agents - therapeutic use (615) 615
quality of life (600) 600
skin - drug effects (596) 596
retrospective studies (592) 592
dermatologic agents - pharmacology (587) 587
psoriasis - pathology (563) 563
time factors (550) 550
aged, 80 and over (548) 548
follow-up studies (545) 545
dermatitis, atopic - drug therapy (544) 544
management (542) 542
calcitriol - analogs & derivatives (537) 537
usage (533) 533
methotrexate - therapeutic use (532) 532
atopic dermatitis (531) 531
administration, oral (528) 528
risk factors (527) 527
prospective studies (515) 515
infant (511) 511
child, preschool (507) 507
ointments (504) 504
clinical trials (488) 488
medical research (486) 486
methotrexate (484) 484
calcitriol - therapeutic use (475) 475
etanercept (471) 471
inflammation (460) 460
isotretinoin - therapeutic use (458) 458
cyclosporine - therapeutic use (444) 444
dosage and administration (442) 442
dermatitis (438) 438
medicine, experimental (436) 436
disease (431) 431
cancer (422) 422
medicine & public health (418) 418
drug combinations (413) 413
quality-of-life (412) 412
psoriasis - therapy (408) 408
dermatology & venereal diseases (399) 399
mice (395) 395
medicine, general & internal (390) 390
eczema (388) 388
adrenal cortex hormones - therapeutic use (387) 387
chronic disease (381) 381
corticosteroids (379) 379
dose-response relationship, drug (376) 376
vulgaris (372) 372
pediatrics (370) 370
diagnosis, differential (369) 369
drug administration schedule (360) 360
tumor necrosis factor-alpha - antagonists & inhibitors (359) 359
isotretinoin (358) 358
phototherapy (353) 353
patients (344) 344
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (36) 36
Online Resources - Online (30) 30
Collection Dvlpm't (Acquisitions) - Vendor file (8) 8
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Gerstein Science - Circulation Desk (2) 2
Providence Healthcare - Reference (2) 2
Credit Valley Hospital - Online (1) 1
Gerstein Science - Reference (1) 1
Mt Sinai Hospital - Online (1) 1
Online (1) 1
Pharmacy (1) 1
St. Michael's Hospital - Online (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13847) 13847
German (694) 694
French (619) 619
Spanish (243) 243
Italian (201) 201
Russian (170) 170
Dutch (62) 62
Portuguese (61) 61
Polish (41) 41
Danish (34) 34
Hungarian (33) 33
Swedish (25) 25
Norwegian (24) 24
Japanese (23) 23
Czech (19) 19
Finnish (11) 11
Romanian (11) 11
Hebrew (7) 7
Bulgarian (6) 6
Chinese (5) 5
Ukrainian (5) 5
Turkish (4) 4
Croatian (3) 3
Slovak (3) 3
Serbian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Academy of Dermatology, ISSN 0190-9622, 2019, Volume 80, Issue 4, pp. 1029 - 1072
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2017, Volume 76, Issue 4, pp. 736 - 744
New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase–signal transducer and activator of transcription... 
Dermatology | JAK-STAT | psoriasis | baricitinib | vitiligo | atopic dermatitis | JAK inhibitor | ruxolitinib | alopecia areata | tofacitinib | RHEUMATOID-ARTHRITIS | OCLACITINIB APOQUEL(R) | OPEN-LABEL | DERMATOLOGY | LONG-TERM EXTENSION | PHASE 2B TRIAL | ALOPECIA-AREATA | ATOPIC-DERMATITIS | JANUS KINASE INHIBITOR | PLAQUE PSORIASIS | TOFACITINIB CITRATE | Pyrazoles - therapeutic use | Dermatitis, Atopic - enzymology | Humans | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Vitiligo - drug therapy | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Psoriasis - drug therapy | Vitiligo - enzymology | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Clinical Trials as Topic | Dermatologic Agents - classification | Janus Kinases - antagonists & inhibitors | Dermatitis, Atopic - drug therapy | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Medical colleges | Psoriasis | Atopic dermatitis | Formulae, receipts, prescriptions | Dermatologic agents | Pharmaceutical industry | Tyrosine | Interleukins | Interferon | Biological response modifiers | T cells | Tofacitinib
Journal Article
Journal of drugs in dermatology, ISSN 1545-9616, 2002
Journal
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9747, pp. 1175 - 1185
Summary Lymphatic filariasis and onchocerciasis are parasitic helminth diseases that constitute a serious public health issue in tropical regions. The filarial... 
Internal Medicine | GLOBAL PROGRAM | DOXYCYCLINE TREATMENT | MEDICINE, GENERAL & INTERNAL | ENDOSYMBIOTIC WOLBACHIA-BACTERIA | BANCROFTIAN FILARIASIS | CLINICAL-TRIAL | WUCHERERIA-BANCROFTI | GROWTH FACTOR-A | MACROFILARICIDAL ACTIVITY | ENDEMIC FOCI | BRUGIA-MALAYI | Onchocerciasis - complications | Prevalence | Age Factors | Elephantiasis, Filarial - transmission | Humans | Elephantiasis, Filarial - epidemiology | Dermatologic Agents - therapeutic use | Onchocerciasis - transmission | Onchocerciasis - epidemiology | Anti-Bacterial Agents - therapeutic use | Filaricides - therapeutic use | Blindness - parasitology | Elephantiasis, Filarial - physiopathology | Onchocerciasis - diagnosis | Diethylcarbamazine - therapeutic use | Drug Therapy, Combination | Elephantiasis, Filarial - complications | Dermatitis - parasitology | Symbiosis | Albendazole - therapeutic use | Elephantiasis, Filarial - diagnosis | Ivermectin - therapeutic use | Doxycycline - therapeutic use | Lymphangitis - parasitology | Wolbachia - drug effects | Africa South of the Sahara | Gram-Negative Bacterial Infections - complications | Lymphadenitis - parasitology | India | Onchocerciasis - physiopathology | Animals | Culicidae | Onchocerciasis - drug therapy | Antinematodal Agents - therapeutic use | Granuloma - parasitology | Macrolides - therapeutic use | Elephantiasis, Filarial - drug therapy | Lymphedema - parasitology | Control | Filariasis | Anti-infective agents | Dosage and administration | Research | Drug therapy | Onchocerciasis | Risk factors | Lymphatic system | Disease | Nematodes | Skin diseases | Parasites | Vascular endothelial growth factor | Tropical diseases | Worms | Community | Chronic illnesses
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2017, Volume 76, Issue 4, pp. 745 - 753.e19
.... Objective Our aim was to systematically review the available data on the use of JAK inhibitors in cutaneous diseases... 
Dermatology | dermatology | psoriasis | baricitinib | vitiligo | atopic dermatitis | ruxolitinib | alopecia areata | JAK inhibitors | graft versus host disease | tofacitinib | CONSTITUTIVE ACTIVATION | LUPUS-ERYTHEMATOSUS | T-CELL LYMPHOMA | VERSUS-HOST-DISEASE | LONG-TERM EXTENSION | ALOPECIA-AREATA | JAK1/2 INHIBITOR | CHRONIC PLAQUE PSORIASIS | RANDOMIZED PHASE-III | TOFACITINIB CITRATE | Pyrazoles - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Dermatologic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Anti-Inflammatory Agents - adverse effects | Antineoplastic Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Pyrroles - adverse effects | Pyrroles - therapeutic use | Pyrazoles - adverse effects | Drug Eruptions - etiology | Psoriasis - drug therapy | Azetidines - adverse effects | Alopecia Areata - enzymology | Skin Diseases - drug therapy | Randomized Controlled Trials as Topic | Janus Kinases - antagonists & inhibitors | Alopecia Areata - drug therapy | Azetidines - therapeutic use | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Psoriasis - enzymology | Skin Diseases - enzymology | Mutual fund industry | Lupus | Psoriasis | Dermatologic agents | Arthritis | Non-Hodgkin's lymphomas | T cells | Rheumatoid factor | Atopic dermatitis | Analysis | Formulae, receipts, prescriptions | Respiratory tract diseases | Skin
Journal Article
Cochrane library, ISSN 1465-1858, 2015, Volume 2017, Issue 5, p. CD003262
Background Rosacea is a common chronic skin condition affecting the face, characterised by flushing, redness, pimples, pustules and dilated blood vessels. The... 
oral isotretinoin | Anti‐Infective Agents | H. DISORDERS OF SKIN APPENDAGES (HAIR, NAILS, SWEAT GLANDS) | Dicarboxylic Acids | Quinoxalines | Brimonidine Tartrate | eradication of Demodex mites | Cyclosporine | Other skin conditions | Dermatologic Agents | Skin disorders | Randomized Controlled Trials as Topic | Tetracycline | oral antibiotics | Doxycycline | Ophthalmic Solutions | topical metronidazole | Metronidazole | Medicine General & Introductory Medical Sciences | Ivermectin | Rosacea | H4 Rosacea | Dicarboxylic Acids [therapeutic use] | Humans | Cyclosporine [therapeutic use] | Metronidazole [therapeutic use] | TARTRATE GEL 0.5-PERCENT | Rosacea [drug therapy] | ANTIINFLAMMATORY DOSE DOXYCYCLINE | SIGNIFICANTLY REDUCES MODERATE | MEDICINE, GENERAL & INTERNAL | Ophthalmic Solutions [therapeutic use] | SODIUM SULFACETAMIDE 10-PERCENT | PULSED DYE-LASER | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | Anti-Infective Agents [therapeutic use] | ACID 15-PERCENT GEL | Dermatologic Agents [therapeutic use] | Doxycycline [therapeutic use] | SEVERE FACIAL ERYTHEMA | METRONIDAZOLE 0.75-PERCENT CREAM | Ivermectin - therapeutic use | Doxycycline - therapeutic use | Ophthalmic Solutions - therapeutic use | Middle Aged | Tetracycline - therapeutic use | Anti-Infective Agents - therapeutic use | Male | Dermatologic Agents - therapeutic use | Dicarboxylic Acids - therapeutic use | Cyclosporine - therapeutic use | Metronidazole - therapeutic use | Female | Rosacea - drug therapy | Quinoxalines - therapeutic use
Journal Article